Matches in SemOpenAlex for { <https://semopenalex.org/work/W2043900942> ?p ?o ?g. }
- W2043900942 endingPage "560" @default.
- W2043900942 startingPage "548" @default.
- W2043900942 abstract "The efficacy and favorable safety profile of anti-tumor necrosis factor (TNF) agents in the treatment of psoriasis and psoriatic arthritis (PsA) are supported by several randomized controlled studies and meta-analyses. However, some concerns on the long-term safety of these drugs still exist, as these studies generally included small patient numbers and were performed in selected patient populations.This review presents and discusses current evidence on the safety of anti-TNFα agents in patients with psoriasis and PsA, with a focus on European registry studies and case reports of particular importance.Key studies on the safety of anti-TNFα agents in the treatment of adult patients with psoriasis or PsA were identified by a MEDLINE search (last updated 10 November 2011) based on several interrelated queries, with a focus on European registries. Other studies and case reports were included if deemed relevant. Studies concerning other conditions, such as rheumatoid arthritis (RA), were included as appropriate when data in psoriatic disease were unavailable or insufficient.Available data on the safety of anti-TNFα agents such as etanercept in psoriasis and PsA appear reassuring, even if some concerns still exist. Most notably, data suggest a higher incidence of infection and lymphoma amongst patients treated with the anti-TNFα monoclonal antibodies infliximab and adalimumab compared with etanercept.The overall safety profile of monoclonal antibodies in patients with psoriasis, PsA and RA seems less favorable than that of etanercept, particularly in terms of risk of infection and hepatotoxicity." @default.
- W2043900942 created "2016-06-24" @default.
- W2043900942 creator A5012746617 @default.
- W2043900942 creator A5016818733 @default.
- W2043900942 creator A5027417944 @default.
- W2043900942 creator A5037993904 @default.
- W2043900942 creator A5041663371 @default.
- W2043900942 creator A5045414645 @default.
- W2043900942 creator A5061835780 @default.
- W2043900942 creator A5065367798 @default.
- W2043900942 creator A5084575229 @default.
- W2043900942 date "2012-02-02" @default.
- W2043900942 modified "2023-09-25" @default.
- W2043900942 title "Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis" @default.
- W2043900942 cites W1518420099 @default.
- W2043900942 cites W1519438828 @default.
- W2043900942 cites W1558329586 @default.
- W2043900942 cites W1579633379 @default.
- W2043900942 cites W1601972531 @default.
- W2043900942 cites W1607447489 @default.
- W2043900942 cites W1786795173 @default.
- W2043900942 cites W1823274426 @default.
- W2043900942 cites W1965692028 @default.
- W2043900942 cites W1968219642 @default.
- W2043900942 cites W1968286287 @default.
- W2043900942 cites W1969629625 @default.
- W2043900942 cites W1973563124 @default.
- W2043900942 cites W1973939528 @default.
- W2043900942 cites W1974193246 @default.
- W2043900942 cites W1976330583 @default.
- W2043900942 cites W1976595941 @default.
- W2043900942 cites W1977233832 @default.
- W2043900942 cites W1977342421 @default.
- W2043900942 cites W1980745486 @default.
- W2043900942 cites W1986689477 @default.
- W2043900942 cites W1988357329 @default.
- W2043900942 cites W1988488437 @default.
- W2043900942 cites W1991148817 @default.
- W2043900942 cites W2000902902 @default.
- W2043900942 cites W2001143625 @default.
- W2043900942 cites W2001193255 @default.
- W2043900942 cites W2002136854 @default.
- W2043900942 cites W2002818361 @default.
- W2043900942 cites W2007533329 @default.
- W2043900942 cites W2007769122 @default.
- W2043900942 cites W2010454265 @default.
- W2043900942 cites W2012608901 @default.
- W2043900942 cites W2012967198 @default.
- W2043900942 cites W2013291529 @default.
- W2043900942 cites W2013350088 @default.
- W2043900942 cites W2013637744 @default.
- W2043900942 cites W2014075805 @default.
- W2043900942 cites W2015353720 @default.
- W2043900942 cites W2020050449 @default.
- W2043900942 cites W2021830773 @default.
- W2043900942 cites W2023989287 @default.
- W2043900942 cites W2025429375 @default.
- W2043900942 cites W2026439613 @default.
- W2043900942 cites W2027887689 @default.
- W2043900942 cites W2028672514 @default.
- W2043900942 cites W2029993898 @default.
- W2043900942 cites W2030348118 @default.
- W2043900942 cites W2039837467 @default.
- W2043900942 cites W2039950744 @default.
- W2043900942 cites W2046154429 @default.
- W2043900942 cites W2046549669 @default.
- W2043900942 cites W2053849737 @default.
- W2043900942 cites W2056329160 @default.
- W2043900942 cites W2056361036 @default.
- W2043900942 cites W2057448387 @default.
- W2043900942 cites W2057831258 @default.
- W2043900942 cites W2060702171 @default.
- W2043900942 cites W2062557180 @default.
- W2043900942 cites W2066896272 @default.
- W2043900942 cites W2068084270 @default.
- W2043900942 cites W2068205003 @default.
- W2043900942 cites W2068614670 @default.
- W2043900942 cites W2070353058 @default.
- W2043900942 cites W2074142396 @default.
- W2043900942 cites W2075994714 @default.
- W2043900942 cites W2080772504 @default.
- W2043900942 cites W2081833623 @default.
- W2043900942 cites W2081998146 @default.
- W2043900942 cites W2086657837 @default.
- W2043900942 cites W2088976365 @default.
- W2043900942 cites W2091177739 @default.
- W2043900942 cites W2095914275 @default.
- W2043900942 cites W2096575585 @default.
- W2043900942 cites W2099706116 @default.
- W2043900942 cites W2102326359 @default.
- W2043900942 cites W2104488468 @default.
- W2043900942 cites W2105031128 @default.
- W2043900942 cites W2105702418 @default.
- W2043900942 cites W2106249804 @default.
- W2043900942 cites W2109745545 @default.
- W2043900942 cites W2112405467 @default.
- W2043900942 cites W2114872119 @default.
- W2043900942 cites W2115088489 @default.